Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 1998

View Archived Issues

The acetylcholinesterase inhibitor rivastigmine demonstrates neuroprotective potential

Ribozyme progresses in target validation collaboration with Schering AG

Caspase inhibitor demonstrates neuroprotective properties in rats

Cystic fibrosis gene also protects against typhoid fever

Corixa: Q1 1998 highlights

Xoma: Q1 1998 highlights

New agents for schizophrenia from Meiji Seika

Team at Warner-Lambert presents new MMP inhibitors

Maxamine in combination with IL-2 retards prostate tumor growth in rats

NeuralSTEM receives patent protection for CNS stem cell technology

Diatide's Theratide inhibits tumor growth

Solarase approved in Canada

Neuromedica receives patent for anticancer drug

Pentose presents method of viral inactivation and results from trial of anti-HPV drug

Muse approved in South Africa

New COX-2 inhibitors described by Abbott

Orotic acid supplementation as a novel neuroprotective approach

SKB patents another series of IL-8 antagonists

NPY receptor ligands claimed by Agouron

Beneficial cardiovascular effects of estrogen demonstrated in postmenopausal women

Dopamine D4 ligands useful for schizophrenia, anxiety

Beneficial repercussions on cardiovascular morbidity of weight reduction with orlistat

Oral tolerization proves effective in experimental rat model of colitis

AII blocker Bay-10-6734 prevents abnormal VSMC growth in vitro

Warner-Lambert receives marketing rights for YM-087, a vasopressin V1 and V2 receptor antagonist

Rhone-Poulenc Rorer presents new taxane in phase I testing

Therapeutic Antibodies and Searle announce research collaboration

Cell Genesys granted patent covering AAV vector technology

SunPharm presents phase I results of DENSPM at ASCO

New tool identified for exploring the adenosine A3 receptor

Pharmacokinetics and safety of SDZ-RAD reported at transplant meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...